Cargando…

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

AIMS: To examine the changes in coronary, all-cause, and cancer mortality in patients with heterozygous familial hypercholesterolaemia (FH) before and after lipid-lowering therapy with statins. METHODS AND RESULTS: A total of 3382 patients (1650 men) aged <80 years were recruited from 21 lipid cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neil, Andrew, Cooper, Jackie, Betteridge, John, Capps, Nigel, McDowell, Ian, Durrington, Paul, Seed, Mary, Humphries, Steve E.
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2577142/ https://www.ncbi.nlm.nih.gov/pubmed/18840879 http://dx.doi.org/10.1093/eurheartj/ehn422

Ejemplares similares

Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register
por: Humphries, Steve E., et al.
Publicado: (2019)

Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register
por: Humphries, S.E., et al.
Publicado: (2018)

Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study
por: Seed, Mary, et al.
Publicado: (2012)

Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records
por: Iyen, Barbara, et al.
Publicado: (2020)

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1-year growth data
por: Humphries, Steve E., et al.
Publicado: (2018)

The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data
por: Ramaswami, Uma, et al.
Publicado: (2017)

Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia
por: Tada, Hayato, et al.
Publicado: (2023)

Genetic Architecture of Familial Hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

Cardiovascular risk stratification in familial hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2016)

Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries
por: Ramaswami, Uma, et al.
Publicado: (2020)

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK
por: Kerr, Marion, et al.
Publicado: (2017)

Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC)
por: Futema, Marta, et al.
Publicado: (2017)

Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia
por: Futema, Marta, et al.
Publicado: (2012)

Improving the cost-effectiveness equation of cascade testing for familial hypercholesterolaemia
por: Pears, Robert, et al.
Publicado: (2015)

Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
por: Akioyamen, Leo E, et al.
Publicado: (2017)

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
por: Versmissen, Jorie, et al.
Publicado: (2008)

Primary prevention and hypercholesterolaemia: ‘Doc, please, give me the natural statin’
por: Poli, Andrea
Publicado: (2019)

Hypercholesterolaemia – practical information for non-specialists
por: Soran, Handrean, et al.
Publicado: (2017)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
por: Kinnear, Fiona J, et al.
Publicado: (2019)

ANMCO Position Paper: diagnostic–therapeutic pathway in patients with hypercholesterolaemia and statin intolerance
por: Gulizia, Michele Massimo, et al.
Publicado: (2017)

Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care
por: Jones, Matthew, et al.
Publicado: (2022)

Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review
por: Mohd Nor, Noor Shafina, et al.
Publicado: (2019)

Risk factors for cardiovascular events in patients with heterozygous familial hypercholesterolaemia: protocol for a systematic review
por: Mansilla-Rodríguez, María Elena, et al.
Publicado: (2023)

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial
por: Raal, Frederick, et al.
Publicado: (2023)

Case-finding and genetic testing for familial hypercholesterolaemia in primary care
por: Qureshi, Nadeem, et al.
Publicado: (2021)

Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design
por: Tada, Hayato, et al.
Publicado: (2020)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

Functional analysis of four LDLR 5′UTR and promoter variants in patients with familial hypercholesterolaemia
por: Khamis, Amna, et al.
Publicado: (2015)

Association of a sequence variant in DAB2IP with coronary heart disease
por: Harrison, Seamus C., et al.
Publicado: (2012)

Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials
por: Edwards, Jayne E, et al.
Publicado: (2003)

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care
por: Iyen, Barbara, et al.
Publicado: (2021)

Familial hypercholesterolaemia: cholesterol efflux and coronary disease
por: Versmissen, Jorie, et al.
Publicado: (2016)

Hypercholesterolaemia in a vegan.
por: Duggan, B., et al.
Publicado: (1997)

Nutraceuticals in hypercholesterolaemia: an overview
por: Santini, Antonello, et al.
Publicado: (2016)

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
por: Kastelein, John J.P., et al.
Publicado: (2015)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
por: Borissov, Borislav, et al.
Publicado: (2017)

Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration
por: Bellgard, Matthew I, et al.
Publicado: (2017)

Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care
por: Qureshi, Nadeem, et al.
Publicado: (2021)

Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia
por: Ding, Cheng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_10bh903621sfipvg7jdjm5gv1g